AstraZeneca bags three of the month’s four oncology approvals.

Investors will hope for a JP Morgan buying spree, while readouts could come from Kura, Allogene and MacroGenics.

Amid a KRAS data dump, a doublet of RMC-6236 and RMC-6291 was a highlight.

The focus for divarasib in second-line lung is now the head-to-head Krascendo-1 trial.

Approval decisions loom for Opdivo and Lumakras, and earnings season starts again.

Data suggest a path forward for olomorasib plus Keytruda and chemo in PD-L1 low and negative patients.

While Roche, Lilly and Merck push on aggressively, Novartis throws in the towel.

Merck and Daiichi’s first ADC attempt is knocked back, while Geron gets its inaugural approval.